Amgen Forecasts ‘High Teens’ Growth For Biosimilars
Chairman And CEO Bradway Outlines Expectations For Amgen’s Biosimilars Business
Amgen expects future growth in the “high teens” for biosimilars, chairman and CEO Bob Bradway told the J.P. Morgan Healthcare Conference this week, also setting out his aspirations for the firm’s biosimilars pipeline.
